Ascletis Financial Statements From 2010 to 2025
| ASCLF Stock | USD 0.24 0.00 0.00% |
Check Ascletis Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ascletis Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Ascletis financial statements analysis is a perfect complement when working with Ascletis Pharma Valuation or Volatility modules.
Ascletis |
Ascletis Pharma Company Current Valuation Analysis
Ascletis Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Ascletis Pharma Current Valuation | 116.15 M |
Most of Ascletis Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ascletis Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Ascletis Pharma has a Current Valuation of 116.15 M. This is 99.19% lower than that of the Healthcare sector and 97.5% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.3% higher than that of the company.
Ascletis Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ascletis Pharma's current stock value. Our valuation model uses many indicators to compare Ascletis Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ascletis Pharma competition to find correlations between indicators driving Ascletis Pharma's intrinsic value. More Info.Ascletis Pharma is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ascletis Pharma's earnings, one of the primary drivers of an investment's value.About Ascletis Pharma Financial Statements
Ascletis Pharma stakeholders use historical fundamental indicators, such as Ascletis Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Ascletis Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ascletis Pharma's assets and liabilities are reflected in the revenues and expenses on Ascletis Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ascletis Pharma. Please read more on our technical analysis and fundamental analysis pages.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer ASC61 and ASC63 for advanced solid tumors ASC60 to treat solid tumors and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the Peoples Republic of China. Ascletis Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 266 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Ascletis Pink Sheet
Ascletis Pharma financial ratios help investors to determine whether Ascletis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ascletis with respect to the benefits of owning Ascletis Pharma security.